Valisure in the hot seat: New Form 483 over a 2021 inspection as CEO fires back
The notorious drug testing company Valisure, which has made a name for itself by forcing FDA’s hand with some of its safety-related uncoverings, received a letter this week after the FDA uncovered violations at its Connecticut-based testing lab in 2021.
The letter, which was sent on Dec. 5, stated that the FDA is “concerned” that Valisure was not aware of drug supply chain security requirements.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.